2020-2026年感染疾病領域的合作與授權協議

Infectious Diseases Collaboration and Licensing Deals 2020-2026

出版日期: 2026年10月01日 | 出版商:

Current Partnering | 英文 800+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

讓我們利用 1,762 項現有合作與授權協議的訊息，來了解感染疾病領域合作的趨勢。

《2020-2026 年感染疾病領域的合作與許可協議》提供了有關 1762 項與感染疾病相關資產、技術和開發計劃的合作協議的全面資訊。

我們在感染疾病領域的合作涵蓋了極其廣泛的領域，包括疫苗、抗病毒藥物、抗生素、感染疾病物、診斷以及應對已知和新出現的病原體的新興技術。

本報告將這些趨勢匯總在一個資源中，使用戶能夠了解哪些公司正在合作，哪些感染疾病機會正在吸引關注，交易是如何構建的，披露了哪些財務條款，以及交易如何因治療適應症、技術和開發階段而異。

這份報告不只是簡單地列出了交易清單；它結合了全面的市場交易分析和財務基準、主要交易者的信息、詳細的交易記錄以及公開的合約文件。

本報告為感染疾病領域的業務發展、許可、交易來源和評估、公司策略、研發策略、競爭情報分析以及參與負責人的法律團隊提供可操作的資訊和基準資源。

了解感染疾病領域目前的合作狀況

本報告分析了2020年至2026年感染疾病領域的交易狀況，內容包括：

感染疾病領域合作的年度趨勢
按交易類型分類的交易趨勢
按行業
合作關係發展階段
技術類型
適應症
感染疾病領域最活躍的交易商
根據已披露的交易金額，主要交易
感染疾病領域合作活動的趨勢
這使用戶能夠確定他們的活動集中在哪些方面，並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
感染疾病領域合作關係的財務狀況基準分析
財務條款可能因資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析，包括以下項目：

交易總額
預付款
里程碑付款
版稅率
透過分析這些基準背後的具體交易，用戶可以更全面地了解所揭露的經濟數據背後的經濟狀況。
這為內部基準測試、機會評估、交易準備和談判提供了現實的標準。
財務基準最有用的解讀方式不是將其視為個別平均值，而是將其與類似交易的結構和情況結合起來解讀。本報告提供了建立這種背景所需的基礎交易資訊。
確定感染疾病領域的關鍵交易商和潛在的未來合作夥伴。
本報告列出了在感染疾病領域開展合作活動最活躍的公司，並提供交易歷史記錄，以便用戶可以調查這些公司過去的活動。

這有助於用戶識別以下內容：

積極尋求感染疾病領域機會的公司
有潛力的許可和合作研究夥伴
在相關疾病領域多次合作的組織。
積極參與開發過程的公司
對特定病原體、技術或治療方法感興趣的交易商。
競爭對手正在推廣相關的外部創新策略
對於尋求感染疾病相關資產和技術合作夥伴的公司而言，過去的交易歷史可以提供寶貴的見解，了解哪些組織對類似的機會表現出了興趣。
比較針對不同感染疾病適應症和標靶的合作活動。
感染疾病涵蓋多種病原體、適應症、治療和預防方法，每一種都有其獨特的科學、臨床和商業性趨勢。
本報告按治療適應症和治療標靶分析合作關係，使用戶能夠專注於與特定項目和策略關注事項最相關的交易，而不是僅依賴廣泛的市場層級基準。
透過結合對技術和發展階段的分析，用戶可以找到更有意義的可比較交易和潛在的未來合作夥伴關係。
了解感染疾病領域合約的結構
本報告包括聯合研究、授權、開發、研發及其他合作交易。

根據交易詳情和資訊披露，用戶可以調查以下方面：

授予和保留的權利
負責研發工作
授權權
獨家版權
區域權利
智慧財產
發展和監管義務
負責生產和供應
商業化權利
金錢補償
里程碑和版稅
管治
合約期限和終止條款
這些例子對於考慮感染疾病領域合作的適當框架將很有用。
從實際合約文件中學習
本報告提供了部分感染疾病相關交易的基礎合約文件（如有）。

這些合約提供的資訊遠比簡單的標題公告所能展現的要詳細得多，使用戶能夠了解公司如何記錄諸如以下事項：

權利範圍
發展義務
智慧財產
獨家版權
財務狀況
里程碑觸發條件
特許權使用費規定
商業化權利
合約終止及其他談判事項
對於準備和談判與感染疾病相關的合作研究或許可協議的團隊來說，獲取實際的合約措辭可以提供關於類似交易實際結構方式的寶貴見解。
感染疾病領域綜合交易目錄
本報告包含感染疾病領域 1,762 項合作研究和授權協議的綜合目錄，為識別相關的領先交易提供了詳細的資訊來源。

在以下條件下可以查看交易記錄：

公司
技術類型
治療適應症或標靶
合約揭露狀態
每筆交易都與其底層交易記錄相關聯，從而可以存取更多交易資訊和相關合約文件（如有）。
誰該使用這份報告？
業務拓展與授權團隊
識別類似的感染疾病相關交易、潛在合作夥伴和相關交易結構。
研究與評估團隊
我們將確定哪些公司正在積極探索與感染疾病相關的業務機會，以及相關的適應症、技術和發展階段。
尋求合作夥伴的生技公司
找出對類似感染疾病相關資產、技術和開發項目表現出明確興趣的組織。
企業策略與研發策略團隊
我們將了解我們的競爭對手和潛在的未來合作夥伴如何透過外部創新來建立其感染疾病相關產品組合。
競爭情報與市場情報團隊
按公司、適應症、目標、開發階段和技術追蹤合作趨勢，以了解不斷變化的策略重點。
法律及交易團隊
我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
我們將市場範圍內的感染疾病資訊轉化為針對特定公司的洞察。
對於符合資格的客戶，Current Partnering 除了提供報告外，還將為高階主管提供客製化的合作關係簡報。
本簡報將把與感染疾病相關的交易情報應用於您的特定資產、技術、指標、目標或合作目標。
如有需要，我們可以提供相關的類似交易、潛在的未來合作夥伴、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您情況選擇的資訊。
請索取樣本或聯絡 Current Partnering 討論報告內容以及我們是否可以為貴公司提供客製化分析。

The report brings this activity together in one resource, enabling users to understand who is partnering, which infectious disease opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in infectious diseases partnering.

Understand the infectious diseases partnering landscape

The report analyzes infectious diseases dealmaking from 2020 to 2026, including:

Trends in infectious diseases partnering by year
Deal activity by deal type
Industry sector
Stage of development at the time of partnering
Technology type
Therapeutic indication
Most active infectious diseases dealmakers
Leading deals by disclosed value
How infectious diseases partnering activity is evolving
This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
Benchmark infectious diseases deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

Headline deal values
Upfront payments
Milestone payments
Royalty rates
Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading infectious diseases dealmakers and prospective partners
The report identifies the most active companies in infectious diseases partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

Companies actively seeking infectious disease opportunities
Prospective licensing and collaboration partners
Organizations repeatedly partnering in relevant disease areas
Companies active at relevant stages of development
Dealmakers demonstrating interest in specific pathogens, technologies or therapeutic approaches
Competitors pursuing related external innovation strategies
For companies seeking to partner an infectious disease asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
Compare partnering activity across infectious disease indications and targets
Infectious diseases encompass a wide variety of pathogens, indications and treatment or prevention approaches, each with differing scientific, clinical and commercial dynamics.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how infectious diseases agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

Rights granted and retained
Research and development responsibilities
Licensing rights
Exclusivity
Geographic rights
Intellectual property
Development and regulatory obligations
Manufacturing and supply responsibilities
Commercialization rights
Financial consideration
Milestones and royalties
Governance
Term and termination provisions
These real-world examples provide useful reference points when considering the appropriate structure for an infectious diseases partnership.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected infectious diseases transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

Scope of rights
Development obligations
Intellectual property
Exclusivity
Financial terms
Milestone triggers
Royalty provisions
Commercialization rights
Termination and other negotiated provisions
For teams preparing or negotiating an infectious diseases collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
Comprehensive infectious diseases deal directory
The report includes a comprehensive directory of 1,762 infectious diseases collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

Company
Technology type
Therapeutic indication or target
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable infectious diseases transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking infectious disease opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable infectious disease assets, technologies and development programs.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building infectious diseases portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide infectious diseases intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying infectious diseases deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.